Gaia Silvia, Olivero Antonella, Smedile Antonina, Ruella Marco, Abate Maria Lorena, Fadda Maurizio, Rolle Emanuela, Omedè Paola, Bondesan Paola, Passera Roberto, Risso Alessandra, Aragno Manuela, Marzano Alfredo, Ciancio Alessia, Rizzetto Mario, Tarella Corrado
Department of Gastro-hepatology, A.O. Città della Salute e della Scienza, S. Giovanni Battista Hospital, University of Turin, C. Bramante 88, 10126, Turin, Italy.
Division of Hematology and Cell Therapy, University of Torino, Mauriziano Hospital, Turin, Italy.
Hepatol Int. 2013 Oct;7(4):1075-83. doi: 10.1007/s12072-013-9473-9. Epub 2013 Oct 11.
Bone marrow-derived cells (BMCs) include stem cells capable of self-renewal and differentiation into a variety of cell types. Administration of granulocyte colony-stimulating factor (G-CSF) induces the circulation of BMCs in the peripheral blood. A phase II prospective trial was carried out for evaluation of BMC mobilization induced by multiple courses of G-CSF in cirrhotic patients.
Fifteen patients with advanced liver cirrhosis (Child-Pugh score ≥6 points) were enrolled and treated with a 3-day G-CSF course, administered at 3-month intervals for a total of four courses. BMC mobilization was assessed by evaluating CD34+ve cells using flow cytometry. Expressions of multiple hepatic and stem markers were assessed on mobilized CD34+ve cells. Feasibility and safety were explored; clinical and adverse events were compared to those of a control group. Telomere length was monitored to rule out early cell aging caused by G-CSF.
A significant increase in G-CSF-induced circulating CD34+ve cells was consistently observed, although a progressive reduction of peak values was documented from cycle I to IV (p < 0.005). Mobilized CD34+ve cells expressed both stem and multiple hepatocyte markers, including mRNA of albumin and CYP2B6 (cytochrome P2 B6). Treatment was well tolerated, with no severe adverse events and no significant telomere length shortening following G-CSF. The procedure was safe. Overall, ten patients had either improved or had stable liver function tests (such as the Child-Pugh score), whereas five worsened and died from liver-related causes.
This study demonstrates that G-CSF can be safely administrated up to four times over a 1-year period in decompensated cirrhotic patients. The repeated BMC mobilization favors the circulation of stem cells coexpressing hepatic markers and mRNA of liver-related genes.
骨髓来源的细胞(BMCs)包括能够自我更新并分化为多种细胞类型的干细胞。给予粒细胞集落刺激因子(G-CSF)可诱导BMCs在外周血中循环。开展了一项II期前瞻性试验,以评估多疗程G-CSF在肝硬化患者中诱导的BMC动员情况。
纳入15例晚期肝硬化患者(Child-Pugh评分≥6分),给予为期3天的G-CSF疗程治疗,每3个月给药1次,共4个疗程。通过流式细胞术评估CD34+阳性细胞来评估BMC动员情况。对动员的CD34+阳性细胞评估多种肝脏和干细胞标志物的表达。探讨可行性和安全性;将临床和不良事件与对照组进行比较。监测端粒长度以排除G-CSF引起的早期细胞衰老。
持续观察到G-CSF诱导的循环CD34+阳性细胞显著增加,尽管从第I周期到第IV周期记录到峰值逐渐降低(p<0.005)。动员的CD34+阳性细胞表达干细胞和多种肝细胞标志物,包括白蛋白和CYP2B6(细胞色素P2B6)的mRNA。治疗耐受性良好,未出现严重不良事件,G-CSF治疗后端粒长度也未显著缩短。该操作是安全的。总体而言,10例患者的肝功能检查(如Child-Pugh评分)有所改善或保持稳定,而5例患者病情恶化并死于肝脏相关原因。
本研究表明,在失代偿期肝硬化患者中,G-CSF在1年内可安全给药多达4次。重复的BMC动员有利于共表达肝脏标志物和肝脏相关基因mRNA的干细胞循环。